{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:18:36Z","timestamp":1776241116024,"version":"3.50.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["No. B2024265, No. B2025362"],"award-info":[{"award-number":["No. B2024265, No. B2025362"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>Hypogonadism, presenting with low libido, erectile dysfunction, and gynecomastia, frequently occurs in men with hyperprolactinemia, typically characterized by elevated serum prolactin, suppressed gonadotropins, and low testosterone. However, we identified a rare subset of patients who presented with normal testosterone levels, but whose clinical profiles were poorly defined.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A retrospective analysis of medical records was conducted on 23 men diagnosed with idiopathic hyperprolactinemia and normal testosterone levels between 01\/07\/2019 and 01\/12\/2024. Baseline clinical characteristics, hormone levels, pituitary gland dimensions (as measured by MRI-derived pituitary height), and responses to medical treatments (bromocriptine or cabergoline) were evaluated.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The mean age at diagnosis was 30.91\u2009\u00b1\u20097.66 years (range: 20\u201350). Mean serum prolactin at presentation was 38.22\u2009\u00b1\u200930.68\u2009ng\/mL (range: 20.00\u2013170.93), and mean pituitary height was 6.40\u2009\u00b1\u20090.97\u2009mm. Primary complaints at diagnosis included low libido, gynecomastia, impotence, and erectile dysfunction. Eighteen patients received bromocriptine, whereas five patients received cabergoline. After an average treatment duration of 7.83\u2009\u00b1\u20096.97 months (range: 1\u201329 months), prolactin levels normalized in all patients, pituitary height was significantly reduced to 4.39\u2009\u00b1\u20091.37\u2009mm, and most patients reported notable clinical improvements, particularly in sexual function.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Idiopathic hyperprolactinemia-associated hypogonadism can occasionally present with normal testosterone levels, emphasizing the importance of clinical vigilance beyond standard hormonal assessments. Pituitary height reduction may serve as an important diagnostic marker and indicator of treatment effectiveness. Medical treatment, including bromocriptine or cabergoline, with a possible preference for cabergoline based on clinical considerations, can effectively normalize hormone levels and significantly improve clinical symptoms.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0332871","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T17:36:16Z","timestamp":1758216976000},"page":"e0332871","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Idiopathic hyperprolactinemia-associated hypogonadism in men presenting with normal testosterone levels"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-7019","authenticated-orcid":true,"given":"Xiaozhi","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunbei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Er","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiliang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"5","key":"pone.0332871.ref001","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1743-6109.2008.01206.x","article-title":"Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction","volume":"6","author":"G Corona","year":"2009","journal-title":"J Sex Med"},{"issue":"5","key":"pone.0332871.ref002","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.ijir.3901043","article-title":"Hyperprolactinemia and sexual function in men: a short review","volume":"15","author":"J Buvat","year":"2003","journal-title":"Int J Impot Res"},{"issue":"3","key":"pone.0332871.ref003","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11102-013-0497-x","article-title":"Male prolactinomas presenting with normal testosterone levels","volume":"17","author":"I Shimon","year":"2014","journal-title":"Pituitary"},{"issue":"4","key":"pone.0332871.ref004","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000777","article-title":"Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine","volume":"26","author":"R Krysiak","year":"2019","journal-title":"Am J Ther"},{"issue":"3","key":"pone.0332871.ref005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11154-015-9322-3","article-title":"The role of prolactin in andrology: what is new?","volume":"16","author":"G Rastrelli","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"pone.0332871.ref006","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41443-023-00717-1","article-title":"Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire","volume":"36","author":"G Corona","year":"2024","journal-title":"Int J Impot Res"},{"issue":"6","key":"pone.0332871.ref007","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4103\/aja.aja_22_19","article-title":"Effect of prolactin on penile erection: a cross-sectional study","volume":"21","author":"Z-H Xu","year":"2019","journal-title":"Asian J Androl"},{"issue":"1","key":"pone.0332871.ref008","first-page":"39","article-title":"Hyperprolactinemia and erectile dysfunction","volume":"2","author":"SI Zeitlin","year":"2000","journal-title":"Rev Urol"},{"issue":"5","key":"pone.0332871.ref009","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1210\/clinem\/dgac028","article-title":"Relation of Testosterone, Dihydrotestosterone, and Estradiol With Changes in Outcomes Measures in the Testosterone Trials","volume":"107","author":"AJ Stephens-Shields","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"pone.0332871.ref010","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00701-024-06213-9","article-title":"Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma","volume":"166","author":"L Andereggen","year":"2024","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"pone.0332871.ref011","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s12020-021-02624-1","article-title":"True hyperprolactinemia in men without visible pituitary adenoma","volume":"72","author":"I Shimon","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"pone.0332871.ref012","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","article-title":"Prolactin - a pleiotropic factor in health and disease","volume":"15","author":"V Bernard","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"pone.0332871.ref013","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"C Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"issue":"2","key":"pone.0332871.ref014","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1023\/A:1012905415868","article-title":"Current management of prolactinomas","volume":"54","author":"P Nomikos","year":"2001","journal-title":"J Neurooncol"},{"issue":"5","key":"pone.0332871.ref015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5144\/0256-4947.2022.334","article-title":"Epidemiological and clinical profiles of Saudi patients with hyperprolactinemia in a single tertiary care center","volume":"42","author":"M Mahzari","year":"2022","journal-title":"Ann Saudi Med"},{"issue":"3","key":"pone.0332871.ref016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jsxmed\/qdad177","article-title":"Impact of hyperprolactinemia on sexual function","volume":"21","author":"K David","year":"2024","journal-title":"J Sex Med"},{"issue":"2","key":"pone.0332871.ref017","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/153537020623100205","article-title":"eNOS function and dysfunction in the penis","volume":"231","author":"B Musicki","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"key":"pone.0332871.ref018","doi-asserted-by":"crossref","first-page":"117532","DOI":"10.1016\/j.taap.2025.117532","article-title":"Prolactin impairs erectile function via eNOS suppression independently of testosterone","volume":"504","author":"X Cheng","year":"2025","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"pone.0332871.ref019","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11102-025-01548-7","article-title":"Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia","volume":"28","author":"A Milioto","year":"2025","journal-title":"Pituitary"},{"issue":"4","key":"pone.0332871.ref020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5468\/ogs.2019.62.4.249","article-title":"Pituitary magnetic resonance imaging abnormalities in young female patients with hypogonadotropic hypogonadism","volume":"62","author":"J-Y Kang","year":"2019","journal-title":"Obstet Gynecol Sci"},{"issue":"6","key":"pone.0332871.ref021","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/cen.13015","article-title":"The prevalence of structural pituitary abnormalities by MRI scanning in men presenting with isolated hypogonadotrophic hypogonadism","volume":"84","author":"M Dalvi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"pone.0332871.ref022","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.ju.0000082960.84075.54","article-title":"The value of pituitary magnetic resonance imaging in men with hypogonadism","volume":"170","author":"EL Rhoden","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"pone.0332871.ref023","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11102-014-0601-x","article-title":"Pituitary imaging findings in male patients with hypogonadotrophic hypogonadism","volume":"18","author":"D Hirsch","year":"2015","journal-title":"Pituitary"},{"issue":"4","key":"pone.0332871.ref024","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02018614","article-title":"Height of normal pituitary gland as a function of age evaluated by magnetic resonance imaging in children","volume":"21","author":"M Argyropoulou","year":"1991","journal-title":"Pediatr Radiol"},{"issue":"5","key":"pone.0332871.ref025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00247-024-05873-0","article-title":"Pituitary gland height evaluated with magnetic resonance imaging in premature twins: the impact of growth and sex","volume":"54","author":"MI Argyropoulou","year":"2024","journal-title":"Pediatr Radiol"},{"issue":"5","key":"pone.0332871.ref026","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11102-021-01150-7","article-title":"Normative data for pituitary size and volume in the general population between 50 and 66 years","volume":"24","author":"EM Berntsen","year":"2021","journal-title":"Pituitary"},{"issue":"1","key":"pone.0332871.ref027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/ENDO:28:1:101","article-title":"Treatment of pituitary tumors: dopamine agonists","volume":"28","author":"G Iv\u00e1n","year":"2005","journal-title":"Endocrine"},{"issue":"3","key":"pone.0332871.ref028","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1380286","article-title":"Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine","volume":"138","author":"M De Rosa","year":"1998","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"pone.0332871.ref029","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"V dos Santos Nunes","year":"2011","journal-title":"Pituitary"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T17:36:21Z","timestamp":1758216981000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0332871"}},"subtitle":[],"editor":[{"given":"Ghadeer Sabah","family":"Bustani,","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0332871","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}